Hoffmann-La Roche

EQS-News: The OTCQB Venture Market Records 4 Months Of Consecutive Volume Increases In OTC Market Group’s Most-Active List In October

Retrieved on: 
Sunday, November 27, 2022
Bitcoin, Ethereum, Helene Curtis Industries, Inc., Organization, Fidelity, OTC Markets Group, Federal Reserve, ETF, Biotechnology, PLUS, OTCQX, DJA, GBTC, GPO, Most, Anglo American plc, OTCQB, DSM (company), SPDR, Nasdaq Composite, DIA, Hoffmann-La Roche, Cryptocurrency, Coffee

The OTCQB Venture Market recorded $739 million in October, an increase over the $642.6 million in trading volume recorded in September.

Key Points: 
  • The OTCQB Venture Market recorded $739 million in October, an increase over the $642.6 million in trading volume recorded in September.
  • In fact, trading volume in the OTCQB Venture Market has increased on a monthly basis since at least July.
  • Like the OTCQX Best Market, the OTCQB Venture Markets top 10 Most Active list for the month saw new entries.
  • Below are the top 10 most actively traded securities on the OTCQX Best Market and OTCQB Venture Market in October.

AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference

Retrieved on: 
Wednesday, November 23, 2022
Hoffmann-La Roche, AC, RU, Janssen Pharmaceuticals, SG, Eli Lilly and Company, Interim, Neurodegeneration, Precision medicine, KR, Genentech, NO, CH, GB, AU, Safety, Pharmaceutical industry, EU

ACI-35.030 and JACI-35.064, two novel anti-phospho-Tau vaccines for the treatment of Alzheimers Disease: Interim Phase 1b/2a data on safety, tolerability and immunogenicity

Key Points: 
  • ACI-35.030 and JACI-35.064, two novel anti-phospho-Tau vaccines for the treatment of Alzheimers Disease: Interim Phase 1b/2a data on safety, tolerability and immunogenicity
    AC Immune SAis a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimers disease, Parkinsons disease, and NeuroOrphan indications driven by misfolded proteins.
  • SupraAntigen is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU and SG.
  • Morphomer is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.
  • The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

Retrieved on: 
Friday, November 18, 2022
Marketing, COVID-19, BioNTech, Science, Hoffmann-La Roche, Risk, Regeneron Pharmaceuticals, Omicron, BNT162, Pediatrics, Pierre Geneves, RNA transfection, Infection, Cancer, Pfizer–BioNTech COVID-19 vaccine, Research, Form, Originality, Ageing, News, Publication, Clinical trial, Peer review, Immunotherapy, Vaccine, Safety, Medical device, Genentech, Pfizer

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • In addition, to learn more, please visit us on and follow us on Twitter at @Pfizer and @Pfizer News , LinkedIn , YouTube and like us on Facebook at Facebook.com/Pfizer .
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Nykode Therapeutics to announce financial results for the third quarter 2022 and host webcast presentation on November 23, 2022

Retrieved on: 
Wednesday, November 16, 2022
COVID-19, Cervical cancer, Adaptation, OSE, B cell, Hoffmann-La Roche, Regeneron Pharmaceuticals, ASA, Therapy, Oslo Stock Exchange, Papilloma, Cancer, Infection, CET, HPV, Safety, Pharmaceutical industry, Genentech

A live and archived webcast of the presentation can be accessed in the Investors section of the Companys website: https://nykode.com/investors/financial-reports-and-presentations .

Key Points: 
  • A live and archived webcast of the presentation can be accessed in the Investors section of the Companys website: https://nykode.com/investors/financial-reports-and-presentations .
  • Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies for the treatment of cancer and infectious diseases.
  • Nykode Therapeutics shares are traded on the Oslo Stock Exchange (OSE: NYKD).
  • Further information about Nykode Therapeutics may be found at http://www.nykode.com .

Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection

Retrieved on: 
Wednesday, November 16, 2022
Marketing, COVID-19, BioNTech, Science, Hoffmann-La Roche, Risk, Regeneron Pharmaceuticals, Omicron, Pediatrics, Pierre Geneves, RNA transfection, Infection, Cancer, Pfizer–BioNTech COVID-19 vaccine, Research, Form, Originality, News, Publication, Clinical trial, Peer review, Immunotherapy, Vaccine, Safety, BNT162, Genentech, Pfizer

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

BioNTech Expands Global Footprint by Acquiring GMP Manufacturing Site to Establish First mRNA Facility in Singapore

Retrieved on: 
Monday, November 14, 2022
Yee, Immunotherapy, Head, GMP, Regeneron Pharmaceuticals, BioNTech, Senior, BNTX, Infection, Engineering, Form, Geneve 9640, Cancer, Northwestern Bell Telephone Company Regional Headquarters, Acquisition, RNA transfection, Therapy, COVID-19, EDB, The Singapore Economic Review, Hoffmann-La Roche, Vaccine, Aquaculture, Pfizer, Health care, Genentech

The acquisition is part of BioNTechs expansion strategy to strengthen its global footprint in Asia.

Key Points: 
  • The acquisition is part of BioNTechs expansion strategy to strengthen its global footprint in Asia.
  • Supported by the Singapore Economic Development Board (EDB), the facility will serve as BioNTechs Regional Headquarters and become its first mRNA manufacturing facility in Singapore.
  • We are excited to be moving a step closer to expanding our global manufacturing network to Singapore, supporting production of mRNA-based vaccines and therapeutics for the Asia Pacific region.
  • We are delighted that BioNTech has chosen Singapore as the location for its new Regional Headquarters and first mRNA manufacturing facility in the Asia Pacific region.

Lucy Therapeutics Expands Leadership Team with Appointment of Julia Gaebler, Ph.D., as Chief Business Officer

Retrieved on: 
Tuesday, November 15, 2022
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Journal, Graduate school, Johns Hopkins University, Partnership, Infection, Degenerative disease, Therapy, Diagnosis, Lucy, Patient, Mitochondrion, Hoffmann-La Roche, Multimedia, Paul H. Nitze School of Advanced International Studies, Economics, Frederick S. Pardee RAND Graduate School, Health policy, Biomarker, CNS, Research, Doctor of Philosophy, Metabolism, Genetics, University, Disease, M.A, Harvard University, Growth, Central nervous system, Multiple sclerosis, Rett syndrome, Drug discovery, Public health, Gaebler Children's Center, University of California, The Journal of Pediatrics, Society for Vascular Surgery, Health, Medtech, Rett, Pharmaceutical industry, Nature, Biogen, Pediatrics

Lucy Therapeutics, Inc., a private biotech company developing proprietary mitochondrial-based small molecule therapies and biomarkers for neurological diseases, today announced the appointment of business-side biopharma leader Julia Gaebler, Ph.D., as Chief Business Officer.

Key Points: 
  • Lucy Therapeutics, Inc., a private biotech company developing proprietary mitochondrial-based small molecule therapies and biomarkers for neurological diseases, today announced the appointment of business-side biopharma leader Julia Gaebler, Ph.D., as Chief Business Officer.
  • Dr. Gaebler has more than 25 years of business development and strategy experience in the life sciences industry, across biopharma, consulting, and academia.
  • View the full release here: https://www.businesswire.com/news/home/20221115005644/en/
    Dr. Gaebler will direct Lucy Therapeutics fundraising, growth and partnership activities for its promising proprietary preclinical compounds in Parkinsons disease, Rett syndrome, and other diseases of mitochondrial dysfunction.
  • Prior to joining Lucy Therapeutics, Dr. Gaebler was vice president of commercial strategy and portfolio planning at Milestone Pharmaceuticals and partner at Health Advances, a life-sciences strategy consulting firm.

Genentech Provides Update on Phase III GRADUATE Program Evaluating Gantenerumab in Early Alzheimer’s Disease

Retrieved on: 
Thursday, November 24, 2022
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, Memory, Data, Immunoglobulin G, Public health, Disease, RO, ADAS-Cog, Incidence, II, Conference, ROG, Autism, Cerebrospinal fluid, Multiple sclerosis, Neuroscience, Biotechnology, CSF, Diagnosis, Roche, Orientation, Hoffmann-La Roche, Stroke, Science, MMSE, Edema, Hobby, ARIA, Hope, Health, Brain, Clinical Dementia Rating, Research, Phase, News, Clinical trial, MCI, Multimedia, Problem solving, Alzheimer's disease, Microglia, Safety, Judgement, Fine chemical, Medical imaging, Pharmaceutical industry, MorphoSys, Gantenerumab, Genentech

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the Phase III GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment (MCI) due to Alzheimers and mild Alzheimers dementia, collectively called early Alzheimers disease.

Key Points: 
  • Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the Phase III GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment (MCI) due to Alzheimers and mild Alzheimers dementia, collectively called early Alzheimers disease.
  • This represents a relative reduction in clinical decline of 8% in GRADUATE I and 6% in GRADUATE II compared with placebo.
  • Genentech will present topline findings from the GRADUATE I and II studies at the upcoming Clinical Trials on Alzheimers Disease (CTAD) Conference on Wednesday, November 30, 2022 at 4:15 p.m. PT.
  • Genentech and Roche are investigating more than a dozen medicines for neurological disorders including multiple sclerosis, stroke, Alzheimers disease, Parkinsons disease and autism spectrum disorder.

Roche receives FDA approval for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE

Retrieved on: 
Tuesday, November 15, 2022
Organic, Food and Drug Administration, Folate receptor 1, Benchmark, Health, Society, FOLR1, Dow Jones, Ovarian cancer, ROG, Paclitaxel, RO, Woman, IHC, Hoffmann-La Roche, Fallopian tube, Research, Gynaecology, Genentech, Biomarker, FDA, Immunohistochemistry, Carboplatin, Dick's Picks Volume 32, ADC, Accelerated approval (FDA), Patient, Fibroadenoma, Veni, vidi, vici, Pharma, Roche Diagnostics, International Agency for Research on Cancer, ImmunoGen, US Foods, Analytic, Food, Disease, EOC, Clear-cell ovarian carcinoma, Medical imaging, Pharmaceutical industry, Fine chemical, Chugai Pharmaceutical Co., Cojocaru, Diagnosis, Cancer

The new test identifies ovarian cancer patients eligible for targeted treatment with ELAHERE.

Key Points: 
  • The new test identifies ovarian cancer patients eligible for targeted treatment with ELAHERE.
  • ELAHERE is a first-in-class antibody-drug conjugate (ADC) therapy developed by ImmunoGen, Inc., approved under FDA's Accelerated Approval program for the treatment of FR-positive platinum-resistant ovarian cancer.
  • "We're proud to expand our women's health and oncology portfolios through the addition of the first companion diagnostic IHC test for ovarian cancer," said Jill German, Head of Pathology Lab at Roche Diagnostics.
  • "This test will enable clinicians to make more informed treatment decisions for patients with ovarian cancer by quickly determining whether they qualify for ELAHERE therapy, potentially improving their outcomes."

Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies

Retrieved on: 
Monday, November 14, 2022
BMY, PDAC, Merrimack Pharmaceuticals, TSX, RNA transfection, Idleness, Mortality, ORR, The New England Journal of Medicine, BioNTech, Irinotecan, Oncolytics Biotech, News, Hoffmann-La Roche, BNTX, Cancer, CBR, Eli Lilly and Company, FDA, Entrepreneurship, BMS, Optimism, Survival, Research, NYSE, Lenalidomide, Pancreatic cancer, LLY, Bristol Myers Squibb, Celgene, Rituximab, Profile, Patient, Breast, CEO, NASDAQ, CR, ONC, SITC, PD-L1, OTC, Lung, Letter, Ipsen, OTCQX, Pharmaceutical industry, Genentech, Pelareorep, Gemcitabine

VANCOUVER, British Colombia, Nov. 14, 2022 /PRNewswire/ -- USA News Group  -  English actor, comedian and Monty Python alumnus Eric Idle credits early detection for his victory over pancreatic cancer, known as the world's deadliest common cancer. "The good news is that we are starting to fight back," said Idle after creating the Bright Side Fund to support research and help promote early detection. Despite US cancer death rates being down across all age groups, however mortality rates for pancreatic cancers have gone up, so there's much work to be done. Now there's developments in the fight against pancreatic cancer coming that are generating huge amounts of optimism from biotech groups such as Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Roche Holding AG (OTCQX: RHHBY), Eli Lilly and Company (NYSE: LLY), Bristol-Myers Squibb Company (NYSE: BMY), and BioNTech SE (NASDAQ: BNTX).

Key Points: 
  • One of the most promising new data sets in pancreatic cancer therapies is coming from pelareorep, developed by Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC).
  • Highlighting the impressive significance of the data, Oncolytics Biotech cites the Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine study published in 2013 by Dr.
  • Back in June, Oncolytics Biotech announced it had achieved success criteria for efficacy in its pancreatic cancer cohort.
  • Back in June, BioNTech presented preliminary Phase I data of its BNT122, evaluating with Genentech (a Roche subsidiary) in pancreatic cancer.